LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 17.2% in February

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 25,100 shares, a drop of 17.2% from the January 31st total of 30,300 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 435,300 shares, the short-interest ratio is presently 0.1 days.

LAVA Therapeutics Price Performance

LVTX traded up $0.04 during trading on Wednesday, hitting $1.32. The stock had a trading volume of 151,643 shares, compared to its average volume of 591,244. The company has a 50 day moving average price of $1.01 and a 200-day moving average price of $1.42. LAVA Therapeutics has a one year low of $0.85 and a one year high of $4.21. The firm has a market cap of $34.70 million, a price-to-earnings ratio of -1.28 and a beta of 0.57.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). As a group, sell-side analysts predict that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on LVTX. HC Wainwright reissued a “neutral” rating and set a $1.50 price target (down from $2.00) on shares of LAVA Therapeutics in a research report on Thursday, February 27th. JMP Securities reissued a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating, According to MarketBeat, LAVA Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LVTX. Virtu Financial LLC bought a new position in LAVA Therapeutics in the third quarter valued at approximately $32,000. BNP Paribas Financial Markets bought a new position in shares of LAVA Therapeutics in the 4th quarter valued at $40,000. Finally, Sanofi acquired a new position in shares of LAVA Therapeutics during the 4th quarter worth $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.